Midwest Trust Co Invests $38.38 Million in Eli Lilly and Company $LLY

Midwest Trust Co purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 49,237 shares of the company’s stock, valued at approximately $38,382,000.

A number of other institutional investors also recently bought and sold shares of the stock. PNC Financial Services Group Inc. grew its holdings in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Nuveen LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter valued at approximately $4,613,912,000. Vanguard Group Inc. lifted its stake in shares of Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Eli Lilly and Company by 106.8% during the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after purchasing an additional 765,010 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock worth $4,808,443,000 after purchasing an additional 682,203 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

LLY opened at $923.35 on Friday. The firm has a market cap of $872.92 billion, a PE ratio of 60.35, a P/E/G ratio of 1.21 and a beta of 0.43. The stock has a 50-day moving average price of $799.97 and a 200-day moving average price of $775.40. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $955.46. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Insider Activity

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased 4,314 shares of company stock worth $2,766,929 over the last three months. 0.13% of the stock is currently owned by insiders.

Analysts Set New Price Targets

LLY has been the subject of a number of research reports. The Goldman Sachs Group increased their price objective on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, November 3rd. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, Berenberg Bank restated a “hold” rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $960.88.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.